Why This Matters: President Trump’s recent announcement that all 50 states will adopt his most-favoured nation (MFN) drug pricing approach could impact the launch of new medicines in Canada — potentially widening an access gap Canadians already face.
Summary: The U.S. most-favoured nation drug pricing approach aims to bring American prices down from the highest in the world to levels that are comparable to other countries, including Canada. To make up for — or avoid — lost revenue in the U.S. due to MFN, pharmaceutical companies may delay or skip launching new medicines in Canada unless we improve our market access environment.